These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 10052993)

  • 1. Characterization of racemic species of chiral drugs using thermal analysis, thermodynamic calculation, and structural studies.
    Li ZJ; Zell MT; Munson EJ; Grant DJ
    J Pharm Sci; 1999 Mar; 88(3):337-46. PubMed ID: 10052993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solubility, metastable zone width, and racemic characterization of propranolol hydrochloride.
    Wang X; Wang XJ; Ching CB
    Chirality; 2002 May; 14(4):318-24. PubMed ID: 11968072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a solid solution of enantiomers in a racemate-forming system by seeding.
    Huang J; Chen S; Guzei IA; Yu L
    J Am Chem Soc; 2006 Sep; 128(36):11985-92. PubMed ID: 16953640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of screening solid-state phases of a racemic modification of a chiral drug: thermodynamic and structural characterization of solid-state phases of etiracetam.
    Herman C; Vermylen V; Norberg B; Wouters J; Leyssens T
    Acta Crystallogr B Struct Sci Cryst Eng Mater; 2013 Aug; 69(Pt 4):371-8. PubMed ID: 23873062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the characterization and crystallization of 4-hydroxy-2-pyrrolidone.
    Wang XJ; Wiehler H; Ching CB
    Chirality; 2004 May; 16(4):220-7. PubMed ID: 15034904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase diagram of (R)- and (S)-4-hydroxy-2-pyrrolidone mixtures: a new case of a conglomerate-forming system.
    Di Silvestro G; Palmisano G; Pellegata R
    J Pharm Sci; 1993 Jul; 82(7):758-60. PubMed ID: 8360853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of molecular flexibility on double polymorphism, solid solutions and chiral discrimination during crystallization of diprophylline enantiomers.
    Brandel C; Amharar Y; Rollinger JM; Griesser UJ; Cartigny Y; Petit S; Coquerel G
    Mol Pharm; 2013 Oct; 10(10):3850-61. PubMed ID: 23984951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three different types of chirality-driven crystallization within the series of uniformly substituted phenyl glycerol ethers.
    Bredikhin AA; Bredikhina ZA; Novikova VG; Pashagin AV; Zakharychev DV; Gubaidullin AT
    Chirality; 2008 Nov; 20(10):1092-103. PubMed ID: 18767134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formation of the racemic compound of ephedrine base from a physical mixture of its enantiomers in the solid, liquid, solution, or vapor state.
    Duddu SP; Grant DJ
    Pharm Res; 1992 Aug; 9(8):1083-91. PubMed ID: 1409382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid tryptophan as a pseudoracemate: physicochemical and crystallographic characterization.
    Li Y; Zhao Y; Zhang Y
    Chirality; 2015 Jan; 27(1):88-94. PubMed ID: 25354341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The binary phase diagram of propranolol hydrochloride and crystallization-based enantioseparation.
    Polenske D; Lorenz H; Seidel-Morgenstern A
    J Pharm Sci; 2010 Apr; 99(4):1762-73. PubMed ID: 19798754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thermodynamic and structural aspects of sulfonamide crystals and solutions.
    Perlovich GL; Tkachev VV; Strakhova NN; Kazachenko VP; Volkova TV; Surov OV; Schaper KJ; Raevsky OA
    J Pharm Sci; 2009 Dec; 98(12):4738-55. PubMed ID: 19408296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racemic species of sodium ibuprofen: characterization and polymorphic relationships.
    Zhang GG; Paspal SY; Suryanarayanan R; Grant DJ
    J Pharm Sci; 2003 Jul; 92(7):1356-66. PubMed ID: 12820140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solubility properties of racemic praziquantel and its enantiomers.
    el-Arini SK; Giron D; Leuenberger H
    Pharm Dev Technol; 1998 Nov; 3(4):557-64. PubMed ID: 9834959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modeling study of chiral drug crystals: lattice energy calculations.
    Li ZJ; Ojala WH; Grant DJ
    J Pharm Sci; 2001 Oct; 90(10):1523-39. PubMed ID: 11745711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Aspects of Solid Solutions of Enantiomers.
    Brandel C; Petit S; Cartigny Y; Coquerel G
    Curr Pharm Des; 2016; 22(32):4929-4941. PubMed ID: 27510486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple approaches to pharmaceutical polymorphism investigation--a case study.
    Li H; Kiang YH; Jona J
    Eur J Pharm Sci; 2009 Dec; 38(5):426-32. PubMed ID: 19748574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of molecular chirality on racemate stability: alpha-amino acids with nonpolar R groups.
    Huang J; Yu L
    J Am Chem Soc; 2006 Feb; 128(6):1873-8. PubMed ID: 16464087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation of solid solutions between racemic and enantiomeric citalopram oxalate.
    de Diego HL; Bond AD; Dancer RJ
    Chirality; 2011 May; 23(5):408-16. PubMed ID: 21472783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of configuration around the chiral carbon atoms on the crystal properties of ephedrinium and pseudoephedrinium salicylates.
    Duddu SP; Grant DJ
    Pharm Res; 1994 Nov; 11(11):1549-56. PubMed ID: 7870670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.